SCHEMBL2614697

SCHEMBL2614697

CO[C@H]1C(OC(C)C)[C@@H](COC(C)C)O[C@H]1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1699642 1.00
SCHEMBL25504579 1.00
SCHEMBL19068391 1.00
SCHEMBL10072494 0.85
SCHEMBL19543056 0.83
SCHEMBL19068316 0.83
SCHEMBL15025160 0.83
SCHEMBL769699 0.83
SCHEMBL1699657 0.83
SCHEMBL26254814 0.82 ALDH1A1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9694077-B2 Lipid compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2017-07-04 US disclosed
US-9540682-B2 Double-stranded nucleic acid, use and kit thereof in ribonuclease detection Suzhou Ribo Life Science Co., Ltd. (CN) 2017-01-10 US disclosed
US-20160274089-A1 SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (CA) 2016-09-22 US disclosed
US-20160272967-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND USES THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2016-09-22 US disclosed
US-9394234-B2 Lipid formulations ARBUTUS BIOPHARMA CORPORATION (CA) 2016-07-19 US disclosed
US-9328348-B2 Small interference RNAs, uses thereof and method for inhibiting the expression of plk1 gene Suzhou Ribo Life Science Co., Ltd. (CN) 2016-05-03 US disclosed
US-20160095924-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-04-07 US disclosed
US-9139554-B2 Amino lipids and methods for the delivery of nucleic acids TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-09-22 US disclosed
US-20150190515-A1 LIPID COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (CA) 2015-07-09 US disclosed
US-20150166465-A1 LIPID FORMULATIONS BANK OF AMERICA, N.A. 2015-06-18 US disclosed
US-20120225434-A1 SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120183602-A1 LIPID FORMULATION ALNYLAM PHARMACEUTICALS, INC. (US) 2012-07-19 US disclosed
US-20120128760-A1 LIPID COMPOSITIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-20120101148-A1 LIPID FORMULATION ALNYLAM PHARMACEUTICALS, INC. (US) 2012-04-26 US disclosed
US-8158601-B2 Lipid formulation ALNYLAM PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-20110256175-A1 AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-10-20 US disclosed
US-20110117125-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2011-05-19 US disclosed
US-20110097720-A1 SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20100324120-A1 LIPID FORMULATION BANK OF AMERICA, N.A. 2010-12-23 US disclosed
US-20100222417-A1 Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues ALNYLAM PHARMACEUTICALS (US) 2010-09-02 US disclosed